[Webinar] Protecting and Patenting Medical Technology From APIs to AI: A Global Comparison - March 18th, 5:00 Pm - 6:00 Pm ET

Why It Matters

Effective IP protection is critical for med‑tech firms to secure competitive advantage and attract investment in an increasingly AI‑driven market.

Key Takeaways

• Global patent rules differ markedly across major markets
• AI-driven medical devices face stricter eligibility criteria
• PCT filings streamline international protection for med‑tech
• Webinar offers CLE credit and actionable IP strategies

Pulse Analysis

The rapid convergence of software, APIs, and artificial intelligence within medical devices has transformed the sector, creating unprecedented opportunities and complex IP challenges. Companies now must safeguard algorithms, data interfaces, and hardware innovations alike, as each component can be a target for competitors. Robust patent strategies that encompass both traditional hardware and emerging digital elements are essential to maintain market advantage and attract investment. Moreover, regulatory bodies such as the FDA increasingly scrutinize algorithmic transparency, linking compliance to patent defensibility.

Jurisdictional nuances further complicate protection. In the United States, patent eligibility for software‑driven medical tools hinges on the Supreme Court’s Alice framework, while Australia applies a stricter “inventive step” test that can reject AI‑based claims lacking tangible contribution. Common pitfalls include over‑broad claims, insufficient disclosure of data training sets, and failure to file timely international applications under the PCT. Strategic use of the Patent Cooperation Treaty (PCT) and regional filings can streamline protection while aligning with local substantive standards. Understanding these differences prevents costly re‑examinations and preserves global enforceability.

The upcoming Wolf Greenfield and FPA Patent Attorneys webinar offers a practical roadmap for navigating these complexities. Attendees will receive actionable guidance on filing strategies, claim drafting, and risk mitigation across key markets, plus the opportunity to ask live questions tailored to their portfolios. The session also counts toward New York CLE credits, making it a valuable professional development resource for IP counsel and med‑tech executives seeking to future‑proof their innovations. By addressing both legal and technical dimensions, the webinar equips participants to align IP with product roadmaps, accelerating time‑to‑market.